Scapho 150mg Secukinumab Injection
Indications / Uses
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Active psoriatic arthritis, alone or in combination w/ methotrexate; when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Dosage / Direction for Use
Plaque psoriasis 300 mg by SC inj w/ initial dosing at wk 0, 1, 2 & 3 followed by mthly maintenance dosing starting at wk 4. Each 300 mg is given as 2 SC inj of 150 mg. Psoriatic arthritis 150 mg SC inj w/ initial dosing at wk 0, 1, 2 & 3, followed by mthly maintenance dosing starting at wk 4. Patients who are anti-TNFα inadequate responders or w/ concomitant moderate to severe plaque psoriasis 300 mg by SC inj w/ initial dosing at wk 0, 1, 2 & 3, followed by mthly maintenance dosing starting at wk 4. Ankylosing spondylitis 150 mg by SC inj w/ initial dosing at wk 0, 1, 2 & 3, followed by mthly maintenance dosing starting at wk 4.
Contraindications
Hypersensitivity.
Special Precautions
Patients w/ chronic or history of recurrent infection; active Crohn’s disease. Should not be given to patients w/ active TB; consider anti-TB therapy prior to initiation in patients w/ latent TB. Discontinue immediately & initiate appropriate therapy in rare case of anaphylactic or other serious allergic reactions. Not to be given concurrently w/ live vaccines. Pregnancy & lactation.
Side Effects / Adverse Reactions
Upper resp tract infections (eg, nasopharyngitis, rhinitis, pharyngitis, sinusitis, tonsillitis). Oral herpes, diarrhea, urticaria, rhinorrhea.
- Free delivery over 00
- 30 Days Return Period
